Cargando…
Clinical trial design for cutaneous neurofibromas
OBJECTIVE: Several clinical trials targeting cutaneous neurofibromas (cNF) have been conducted; however, none has resulted in meaningful changes to care. The Clinical Trial Design and Development subgroup's goals were to (1) define key considerations in the design of clinical trials for cNF, (2...
Autores principales: | Cannon, Ashley, Jarnagin, Kurt, Korf, Bruce, Widemann, Brigitte C., Casey, Denise, Ko, Hon-Sum, Blakeley, Jaishri O., Verma, Sharad K., Pichard, Dominique C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703339/ https://www.ncbi.nlm.nih.gov/pubmed/29987133 http://dx.doi.org/10.1212/WNL.0000000000005790 |
Ejemplares similares
-
Creating a comprehensive research strategy for cutaneous neurofibromas
por: Blakeley, Jaishri O., et al.
Publicado: (2018) -
The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities
por: Brosseau, Jean-Philippe, et al.
Publicado: (2018) -
Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study
por: Cannon, Ashley, et al.
Publicado: (2018) -
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
por: Weiss, Brian D., et al.
Publicado: (2021) -
Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis
por: Fayad, Laura M., et al.
Publicado: (2013)